Company intelligence / Profile preview
ADVANZ PHARMA
- Ownership
- Public · ADVZ
- Employees
- ~700
- Development stage
- Other
Overview
ADVANZ PHARMA is a global pharmaceutical company with commercial products in over 90 countries. Key products include Ocaliva® (obeticholic acid) for Primary Biliary Cholangitis, Mytolac®/Myrelez® (lanreotide) for neuroendocrine tumors, Palmeux® (paliperidone) for schizophrenia, Zonegran® (zonisamide) for epilepsy, and Resolor® (prucalopride succinate) for chronic constipation.
- Therapeutic areas
- Rare DiseasesMetabolic DisordersNeurologyPsychiatryGastroenterologyOncology
- Modalities
- Specialty generics & biosimilarsinnovative medicinesoriginator brands
- Industry
- Biotech
Drug pipeline
6 assets5 more assets in the full pipeline.
Partnerships
Financials
- Market cap
- $1.8B
- Total revenue
- $1.2B
- Enterprise value
- $2.2B
Beyond the preview
Go deeper on ADVANZ PHARMA.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ADVANZ PHARMA.